LU91330I2 - Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus) - Google Patents

Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus)

Info

Publication number
LU91330I2
LU91330I2 LU91330C LU91330C LU91330I2 LU 91330 I2 LU91330 I2 LU 91330I2 LU 91330 C LU91330 C LU 91330C LU 91330 C LU91330 C LU 91330C LU 91330 I2 LU91330 I2 LU 91330I2
Authority
LU
Luxembourg
Prior art keywords
alkyl
aryl
alkoxy
substd
halo
Prior art date
Application number
LU91330C
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91330(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of LU91330I2 publication Critical patent/LU91330I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU91330C 1991-02-21 2007-04-02 Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus) LU91330I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP9658891 1991-04-26
JP13488991 1991-06-06
JP16713891 1991-07-08
JP17397291 1991-07-15
JP18484191 1991-07-24

Publications (1)

Publication Number Publication Date
LU91330I2 true LU91330I2 (fr) 2007-06-04

Family

ID=27549327

Family Applications (4)

Application Number Title Priority Date Filing Date
LU91056C LU91056I2 (fr) 1991-02-21 2004-01-26 Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique.
LU91330C LU91330I2 (fr) 1991-02-21 2007-04-02 Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus)
LU91571C LU91571I2 (fr) 1991-02-21 2009-05-11 Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine
LU91847C LU91847I2 (fr) 1991-02-21 2011-07-26 Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91056C LU91056I2 (fr) 1991-02-21 2004-01-26 Dérivés de 1-biphénylimidazole, leur préparation et leur utilisation thérapeutique.

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91571C LU91571I2 (fr) 1991-02-21 2009-05-11 Une combinaison de olmesartan medoxomil, facultativement sous forme d'un sel pharmaceutiquement acceptable, et d'un bésylate d'amplodipine
LU91847C LU91847I2 (fr) 1991-02-21 2011-07-26 Combinaison de olmesartan medoxomil, optionnellement sous forme d'un sel pharmaceutiquement acceptable, et amlodipine besylate et hydrochlorothiazide

Country Status (22)

Country Link
EP (2) EP0503785B3 (fr)
JP (1) JPH07121918B2 (fr)
KR (1) KR0128289B1 (fr)
CN (3) CN1045770C (fr)
AT (2) ATE200777T1 (fr)
CA (2) CA2229000C (fr)
CZ (1) CZ289194B6 (fr)
DE (6) DE122011000011I1 (fr)
DK (2) DK0503785T3 (fr)
ES (2) ES2156866T3 (fr)
FI (2) FI112942B3 (fr)
GR (2) GR3035906T3 (fr)
HU (3) HU223338B1 (fr)
IE (1) IE920540A1 (fr)
IL (3) IL101034A (fr)
IS (1) IS1756B (fr)
LU (4) LU91056I2 (fr)
NL (3) NL300133I2 (fr)
NO (6) NO304516B3 (fr)
NZ (1) NZ241681A (fr)
PT (2) PT545912E (fr)
RU (1) RU2128173C1 (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0573218B1 (fr) * 1992-06-02 2001-03-07 Sankyo Company Limited Dérivés de 4-carboxyimidazole comme antagonistes de l'angiotensine II et leur application en thérapeutique
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
AU684916B2 (en) * 1994-03-16 1998-01-08 Sankyo Company Limited Ocular tension depressant
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
ES2232873T3 (es) 1996-07-15 2005-06-01 Sankyo Company Limited Composiciones farmaceuticas que comprenden el cs-866 y otros agentes que mejoran la resistencia a la insulina y su uso para el tratamiento de la arterosclerosis y el xantoma.
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
USD441509S1 (en) 1997-08-25 2001-05-01 Mastrad S.A. Combined hand cleaner and hand cleaner base
AU141230S (en) 1999-02-26 2000-07-25 Unilever Plc Detergent tablet
CA2375287A1 (fr) 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Methode de production de derives d'imidazole
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
CA2420844A1 (fr) * 2000-08-30 2003-02-28 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CN1265788C (zh) * 2000-11-21 2006-07-26 三共株式会社 药物组合物
MXPA04001878A (es) * 2001-08-28 2004-06-15 Sankyo Co Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
EP3045174A1 (fr) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Médicament pour la prévention et le traitement de l'artériosclérose et de l'hypertension
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
JP4489020B2 (ja) 2003-04-15 2010-06-23 第一三共株式会社 眼内血管新生性疾患の予防又は治療のための医薬
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
EP2428516A1 (fr) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1713795A2 (fr) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Polymorphes de candesartan cilexetil
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2005089731A2 (fr) 2004-03-17 2005-09-29 Novartis Ag Utilisation de composes organiques
CN1993355A (zh) * 2004-09-02 2007-07-04 特瓦制药工业有限公司 奥美沙坦酯的纯化方法
PT1799199E (pt) 2004-10-08 2012-07-03 Novartis Ag Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
RU2007115900A (ru) 2004-10-27 2008-11-10 Дайити Санкио Компани, Лимитед (Jp) Производные бензола, имеющие 2 или более заместителей
CA2591694A1 (fr) * 2004-12-30 2006-07-13 Teva Pharmaceutical Industries Ltd. Procede de synthese d'olmesartan medoxomil a un ph superieur a 2,5
KR20090108739A (ko) * 2005-01-03 2009-10-16 테바 파마슈티컬 인더스트리즈 리미티드 불순물의 양이 감소된 올메사탄 메독소밀
ES2334386T3 (es) * 2005-04-22 2010-03-09 Daiichi Sankyo Company, Limited Producto farmaceutico para la prevencion o el tratamiento de una enfermedad metabolica osea.
EP1816131A1 (fr) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Procédé pour la préparation du olmesartan medoxomil
EA014026B1 (ru) * 2005-07-29 2010-08-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения олмесартан медоксомила
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (fr) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Formes polymorphes du Olmesartan Medoxomil
CA2642988C (fr) * 2006-02-27 2015-10-27 Takeda Pharmaceutical Company Limited Produit pharmaceutique contenant un benzimidazole en combinaison avec undessechant
ATE526963T1 (de) 2006-05-04 2011-10-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit olmesartan- medoxomil
WO2007148344A2 (fr) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Procédé de préparation d'olmésartan médoxomil
EP1988091B1 (fr) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Composés tricycliques
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
KR20090122455A (ko) * 2007-03-23 2009-11-30 다이이찌 산쿄 가부시키가이샤 올메사탄 메독소밀의 분쇄 결정
EP2865670B1 (fr) 2007-04-18 2017-01-11 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
EP2174666B1 (fr) * 2007-06-22 2013-12-18 Daiichi Sankyo Company, Limited Agent médicamenteux pour le traitement de troubles de la circulation cérébrale ou du flux sanguin cérébral induits par l'amyloïde bêta
CA2727220C (fr) 2008-06-09 2015-07-28 Daiichi Sankyo Company, Limited Procede de fabrication d'un compose de 1-biphenylmethylimidazole
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010016549A1 (fr) 2008-08-06 2010-02-11 協和発酵キリン株式会社 Composé tricyclique
US8618308B2 (en) 2008-11-17 2013-12-31 Shanghai Institute Of Pharmaceutical Industry Process for the preparation of 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylates
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
CA2760031C (fr) 2009-04-28 2015-03-10 Daiichi Sankyo Company, Limited Cristaux solvates d'acetone de trityl olmesartan medoxomil
BRPI1013333B8 (pt) 2009-04-28 2021-05-25 Daichi Sankyo Company Ltd método para produzir olmesartana medoxomila
CA2772488C (fr) 2009-09-11 2018-04-17 Probiodrug Ag Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
EP2521540A2 (fr) 2010-01-05 2012-11-14 Ratiopharm GmbH Forme posologique orale solide contenant de l'olmésartan médoxomil
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (fr) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
CN103874697A (zh) 2011-08-03 2014-06-18 协和发酵麒麟株式会社 二苯并氧杂*衍生物
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN104583185A (zh) 2012-08-31 2015-04-29 株式会社Api 联芳基化合物的制造方法
WO2014051008A1 (fr) 2012-09-26 2014-04-03 株式会社エーピーアイ コーポレーション Procédé de déprotection pour un composé tétrazole
EP2905029B1 (fr) 2012-10-04 2018-11-21 Shionogi&Co., Ltd. Médicament destiné à inhiber une métastase de tumeur maligne
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015012205A1 (fr) 2013-07-23 2015-01-29 第一三共株式会社 Médicament destiné à la prévention ou au traitement de l'hypertension artérielle
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
WO2017164208A1 (fr) 2016-03-24 2017-09-28 第一三共株式会社 Médicament pour le traitement d'une maladie rénale
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0400835A1 (fr) 1989-05-15 1990-12-05 Merck & Co. Inc. Benzimidazoles substitués comme antagoniste d'angiotensine II
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
WO1991012002A1 (fr) * 1990-02-13 1991-08-22 Merck & Co., Inc. Agents antagonistes de l'angiotensine ii a base d'imidazoles dans lesquels est incorpore un element de benzyle substitue
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
NO304517B1 (no) 1999-01-04
HU9601179D0 (en) 1996-07-29
CZ289194B6 (cs) 2001-11-14
AU1112592A (en) 1992-08-27
EP0503785B1 (fr) 2001-04-25
IL114996A0 (en) 1995-12-08
IL101034A0 (en) 1992-11-15
NO2006012I1 (no) 2006-10-30
CA2229000A1 (fr) 1992-08-22
ATE200778T1 (de) 2001-05-15
HK1011969A1 (en) 1999-07-23
RU95101430A (ru) 1997-02-20
NO2009019I1 (no) 2009-09-21
KR0128289B1 (ko) 1998-04-02
HU223338B1 (hu) 2004-06-28
CN1121859C (zh) 2003-09-24
DE69231798T3 (de) 2012-07-12
NL300133I1 (nl) 2003-10-01
FI955248A0 (fi) 1995-11-02
HU211934A9 (en) 1996-01-29
DE10299043I2 (de) 2003-08-07
FI112942B3 (fi) 2012-03-13
AU647887B2 (en) 1994-03-31
DK0545912T3 (da) 2001-06-18
HU9200578D0 (en) 1992-05-28
DE69231798T2 (de) 2001-12-06
FI920749A0 (fi) 1992-02-20
IS1756B (is) 2000-12-28
CA2061607C (fr) 1999-01-19
CN1188645A (zh) 1998-07-29
EP0503785B3 (fr) 2012-02-29
PT545912E (pt) 2001-08-30
IL114996A (en) 1997-07-13
IE970752A1 (en) 2000-02-23
EP0545912A3 (fr) 1993-06-16
DK0503785T3 (da) 2001-06-18
LU91847I2 (fr) 2011-09-26
GR3035906T3 (en) 2001-08-31
NO920688L (no) 1992-08-24
CN1045770C (zh) 1999-10-20
CN1065063A (zh) 1992-10-07
DE69231798D1 (de) 2001-05-31
NL300227I1 (nl) 2006-06-01
FI112942B (fi) 2004-02-13
DE69231801T2 (de) 2001-12-06
FI955248A7 (fi) 1995-11-02
IS3819A (is) 1992-08-22
NL300133I2 (nl) 2004-03-01
NO920688D0 (no) 1992-02-21
CA2061607A1 (fr) 1992-08-22
NO2011013I1 (no) 2011-08-22
EP0503785A1 (fr) 1992-09-16
NO304516B3 (no) 2012-06-11
ES2156866T3 (es) 2001-08-01
CN1189490A (zh) 1998-08-05
FI920749A7 (fi) 1992-08-22
PT503785E (pt) 2001-08-30
JPH0578328A (ja) 1993-03-30
NL300375I1 (nl) 2009-04-01
ATE200777T1 (de) 2001-05-15
NO2003009I2 (en) 2007-12-11
LU91571I2 (fr) 2009-07-13
CN1101384C (zh) 2003-02-12
NO954507D0 (no) 1995-11-09
RU2128173C1 (ru) 1999-03-27
LU91056I2 (fr) 2004-10-19
GR3035909T3 (en) 2001-08-31
NO954507L (no) 1992-08-24
EP0545912A2 (fr) 1993-06-09
NZ241681A (en) 1993-07-27
FI112941B (fi) 2004-02-13
KR920016429A (ko) 1992-09-24
DE122005000051I1 (de) 2006-01-26
HU223667B1 (hu) 2004-11-29
IL101034A (en) 1996-10-16
ES2157895T7 (es) 2012-06-14
CA2229000C (fr) 2002-04-09
HK1011361A1 (en) 1999-07-09
CZ51692A3 (en) 1993-03-17
IE920540A1 (en) 1992-08-26
ES2157895T3 (es) 2001-09-01
NO304516B1 (no) 1999-01-04
DE69231801D1 (de) 2001-05-31
EP0545912B1 (fr) 2001-04-25
HUT60475A (en) 1992-09-28
DE10299043I1 (de) 2003-03-27
DE122011000011I1 (de) 2011-06-16
DE122009000024I1 (de) 2009-09-17
JPH07121918B2 (ja) 1995-12-25

Similar Documents

Publication Publication Date Title
LU91330I2 (fr) Une combinaison d'olmesartan medoxomil, optionnellement sous la forme d'un sel pharmaceutiquement acceptable et d'hydrochlorothiazide (olmetec plus)
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
AR026605A1 (es) Un derivado de 6-mercapto-ciclodextrina, su uso, una composicion farmaceutica que lo comprende, un kit para proporcionar bloqueo neuromuscular y sureversion, y un metodo para la reversion del bloqueo neuromuscular inducido por farmacos
RU96121561A (ru) Применение антагонистов серотонина (5ht3) для лечения фибромиалгии
HU9302497D0 (en) Method for producing new imidazole and pyrimidine derivatives
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
RU2012141061A (ru) Агонист рецептора грелина для лечения кахексии
AR026631A1 (es) ''3-4-dihidroquinazolinas 5,6-disustituidas''
Xie et al. Parthenolide attenuates LPS-induced activation of NF-κB in a time-dependent manner in rat myocardium